Home/ News & Events

ESID COVID-19 Statement, March 2022

Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges.

ESID Position Statement

ESID Position Statement

Joint statement of solidarity and support

ESID is profoundly concerned about the grave repercussions of the conflict in Ukraine on PID community, healthcare and patients. 

Together with IPOPI, INGID and J Project stakeholders, we have released a statement of solidarity and support to those impacted by the war in Ukraine.

Hyper IgM Grant opportunity

ESID is pleased to announce an excellent grant funding opportunity

Study on clinical course of IPEX patients infected with SARS-CoV-2

Call for international contributions relating to IPEX patients infected with SARS-CoV-2.

X-Linked Carrier Survey is now open

The Hyper IgM Foundation and the Wiskott-Aldrich Foundation’s first-ever international 

X-Linked Carrier Surveys are now available! We are excited to launch this survey project in collaboration with the Primary Immune Deficiency Treatment Consortium (PIDTC) and the Immune Deficiency Foundation (IDF). 

Deciphering the immune response against human papillomavirus infection using imaging mass cytometry

Human papillomaviruses (HPVs) are responsible of approximately 5% of cancers worldwide, in particular cervical cancer in women. They are also responsible of recalcitrant warts, and devastating benign tumors such as Buschke-Lowenstein tumor and tree ma...

Independent Survey: SARS-CoV-2 infection in patients with IRAK-4 or MyD88 deficiencies

Dear ESID Member, We at ESID Board want to pay your immediate attention to an ongoing independent survey by the COVID Human Genetic Effort on the clinical characteristics of SARS-CoV-2 infection in patients with IRAK-4 or MyD88 deficiencies. We...

Joint statement on the current epidemics of new Coronavirus

Together with IPOPI, INGID, APSID, ASID, ARAPID, CIS, LASID, SEAPID we have worked on a joint statement to provide guidance in advising patients with primary immunodeficiency under our care in the current COVID-19 context.